AZN: Full year and Q4 2021 results
AstraZeneca PLC 10 February 2022 07:00 GMT Full year and Q4 2021 results Total Revenue increased by 41% and Core EPS by 32% in a year of exceptional pipeline and commercial delivery, coupled with accelerated strategic transformation through the acquisition of Alexion · Total Revenue increased 41% (38% at CER[1]) to $37,417m including COVID-19 vaccine revenues. Total Revenue excluding vaccine increased 26% (23% at CER) to $33,436m. In Q4 2021, Total Revenue increased 62% (63% CER) to $12,011m · Reported[2] EPS[3] of $0.08 (FY 2020: $2.44) and Core[4] EPS of $5.29 (FY 2020: $4.